EpilepsyGTx

Verwendung der Mittel

Accelerate and support lead gene therapy programme EPY201, a locally delivered AAV gene therapy for focal refractory epilepsy, through first-in-human Phase 1/2a clinical trials to establish safety and efficacy, advancing the therapy towards clinical practice.

Alle Investoren (4)

• 
  British Business Bank
• XGEN Venture
• Undisclosed global biopharmaceutical company
• UCL Technology Fund 2

Analyse-Artikel

EpilepsyGTx erhält 33 Millionen US-Dollar für bahnbrechende Gentherapie

Artikel lesen